The trial’s primary efficacy goal is to measure the rate of growth of atrophic lesions in the retina. Credit: SaiArLawKa2 / Shutterstock.com. Belite Bio has concluded the final participant visit in ...

Amidst significant shifts in the pharmaceutical industry, the number of clinical trials has surged over the first half of ...

On this episode, the healthcare editorial team unpicks several key trials and trends from this year’s event, held from 29 August to 1 September in Madrid. Data at ESC is from studies evaluating ...

Revolution will now explore daraxonrasib’s potential as a monotherapy and in combination with chemotherapy in late-stage PDAC trials.

PhaseV has entered into a strategic partnership with Bioforum to enhance the efficiency of clinical trials using advanced ...

Maia Biotechnology’s telomerase modifier, ateganosine (THIO) demonstrated efficacy when given before Regeneron’s immune checkpoint inhibitor Libtayo (cemiplimab) during a Phase II trial in non-small ...

In August, Regeneron announced positive results from Phase III clinical trial NIMBLE evaluating the efficacy and safety of pozelimab + cemdisiran combination therapy and cemdisiran monotherapy for ...

These readouts will help Regeneron structure the confirmatory trials for the two allergy combination therapies.

Paul Hingst, Prasun Mishra, and Naymisha Patel discussed risk management in clinical trials as a key measure to ensure supply and trial success. Credit: Athanasios Psimadis/ Arena International Events ...

Ascletis Pharma’s subcutaneous glucagon-like peptide 1 receptor agonist (GLP-1RA) ASC30 has demonstrated a half-life of 75 days when used as a maintenance therapy for obesity in a Phase Ib trial.